Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Seeger

Showing results (221-230 of 266) with videos related to

Pageof 27
Sort By:
Journal of Virology|November 23, 2000
Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infectionsT Zhou, J T Guo, F A Nunes, et al.
Cancer Cell|April 7, 2009
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcomeSidong Huang, Jamila Laoukili, Mirjam T Epping, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology GroupW B London, R P Castleberry, K K Matthay, et al.
Pediatric Blood & Cancer|July 9, 2015
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastomaClarke P Anderson, Katherine K Matthay, John P Perentesis, et al.
Oncogene|September 22, 1999
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomasC Guo, P S White, M J Weiss, et al.
American Journal of Epidemiology|November 5, 1999
Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology GroupA F Olshan, J Smith, M N Cook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium StudyKatherine K Matthay, Jessica C Tan, Judith G Villablanca, et al.
Medical and Pediatric Oncology|July 24, 2001
Comprehensive analysis of chromosome 1p deletions in neuroblastomaJ M Maris, C Guo, D Blake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group studyK K Matthay, C Perez, R C Seeger, et al.
Pediatric Blood & Cancer|October 22, 2008
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupJulie R Park, Judith G Villablanca, Wendy B London, et al.
Pageof 27

Showing results (221-230 of 266) with videos related to

Sort By:
Pageof 27
Journal of Virology|November 23, 2000
Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infectionsT Zhou, J T Guo, F A Nunes, et al.
Cancer Cell|April 7, 2009
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcomeSidong Huang, Jamila Laoukili, Mirjam T Epping, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology GroupW B London, R P Castleberry, K K Matthay, et al.
Pediatric Blood & Cancer|July 9, 2015
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastomaClarke P Anderson, Katherine K Matthay, John P Perentesis, et al.
Oncogene|September 22, 1999
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomasC Guo, P S White, M J Weiss, et al.
American Journal of Epidemiology|November 5, 1999
Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology GroupA F Olshan, J Smith, M N Cook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium StudyKatherine K Matthay, Jessica C Tan, Judith G Villablanca, et al.
Medical and Pediatric Oncology|July 24, 2001
Comprehensive analysis of chromosome 1p deletions in neuroblastomaJ M Maris, C Guo, D Blake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group studyK K Matthay, C Perez, R C Seeger, et al.
Pediatric Blood & Cancer|October 22, 2008
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupJulie R Park, Judith G Villablanca, Wendy B London, et al.
Pageof 27